drugset / Trial / NCT04474327

Role of Montelukast in Modulation of Response to Sepsis in Preterm Infants

NCT04474327

Phase 1 Completed 40 enrolled Mansoura University Children Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators will conduct this study to explore the role of Montelukast in treatment of neonatal sepsis and whether it has an effect on inflammatory markers, the duration of antibiotic use, or on the patients´ outcome.

Timeline

Start
2020-07-24
Primary completion
2021-02-10
Completion
2021-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 1.5 mg Other
Subject Montelukast Other / unclassified 2 mg Other

Indications